


This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

1. (Currently Amended) A monoalkylaminoketone compound of the formula I



in which


R^1 denotes a saturated, unsaturated or aromatic carbocyclic or heterocyclic thiienyl or furyl radical which is unsubstituted or mono- or polysubstituted by R^3 and/or R^4 , provided that R^1 is not 2,5-dimethyl-3-thienyl,

R^2 denotes alkyl having 1-20 C atoms,

R^3, R^4 each, independently of one another, denote H, alkyl or alkoxy having 1-20 C atoms, aryl, aryloxy or COR^2 , F, Br, OH, CN, NO_2 , $N(R^2)_2$ or $NHCOR^2$,

or a salt thereof.

2. (Withdrawn – Currently Amended) Process for the preparation of a monoalkylaminoketone compound of the formula I




in which

R^1 denotes a saturated, unsaturated or aromatic carbocyclic or heterocyclic thiienyl or furyl radical which is unsubstituted or mono- or polysubstituted by R^3 and/or R^4 , provided that R^1 is not 2,5-dimethyl-3-thienyl,

R^2 denotes alkyl having 1-20 C atoms,

R^3, R^4 each, independently of one another, denote H, alkyl or alkoxy having 1-20 C atoms, aryl, aryloxy or $COOR^2$, F, Br, OH, CN, NO_2 , $N(R^2)_2$ or $NHCOR^2$,


by reacting a compound of the formula II



in which


R^1 and R^2 have the meaning indicated above, in the presence of an alkylamine of the formula R^2NH_2 , in which R^2 has the meaning indicated above.

3. **(Withdrawn – Currently Amended)** Process according to Claim 2, in which R^1 denotes phenyl or 2-thienyl.
4. **(Withdrawn)** Process according to Claim 2, in which R^2 denotes methyl, ethyl, n-propyl or isopropyl.
5. **(Withdrawn)** Process according to claim 2, wherein the pH for the conversion of the compounds of the formula II into the compounds of the formula I is adjusted to about pH 2-7.5 by addition of an alkylamine of the formula R^2NH_2 .
6. **(Withdrawn)** Process according to claim 2, wherein the conversion of the compounds of the formula II into the compounds of the formula I is carried out at $0^\circ - 200^\circ C$.
7. **(Withdrawn – Currently Amended)** Process according to claim 2, wherein firstly the compound of the formula II is obtained by reaction of a mixture of a formaldehyde source with a corresponding alkylammonium salt and a ketone of the formula III




in which R¹ has the meaning indicated in Claim 1 claim 2,
in the presence of a strong acid, and the compounds of the formula II obtained in this way
are employed without further isolation for the preparation of the compounds of the
formula I.

8. **(Withdrawn)** Process for the preparation of compounds of the formula I according to Claim 6, wherein the pH of the strongly acidic reaction mixture comprising the compounds of the formula II is increased to about pH 2-7.5, without further isolation of this compound, by addition of an alkylamine of the formula R²NH₂, and the mixture is subsequently warmed.
9. **(Withdrawn)** Process for the preparation of compounds of the formula I according to Claim 7, wherein the reaction mixture comprising the compounds of the formula II is warmed to 0°C to 200°C after addition of a corresponding alkylamine.
10. **(Withdrawn)** Process according to claim 2 for the preparation of 3-methylamino-1-phenyl-1-propanone or 3-methylamino-1-(2-thienyl)-1-propanone.
11. **(Withdrawn)** Process according to claim 2, wherein an acid-addition salt of the compound of the formula II is employed, and an acid-addition salt of the compound of the formula I is obtained.
12. **(Previously presented)** A compound of claim 1 which is of the formula Ia:



13. **(Previously presented)** A compound of claim 1 which is of the formula Ib:



or a salt thereof.

14. (Cancelled)

15. (Currently Amended) A compound of claim 1, wherein R¹ denotes phenyl or 2-thienyl.

16. (Previously presented) A compound of claim 1, wherein R² denotes methyl, ethyl, n-propyl or isopropyl.

17. (Currently Amended) A compound of claim 1, wherein R¹ is selected from: 2- or 3-furyl, ~~or~~ 2- or 3-thienyl, ~~1~~, ~~2~~, ~~4~~ or 5-imidazolyl, ~~1~~, ~~3~~, ~~4~~ or 5-pyrazolyl, ~~2~~, ~~4~~ or 5-oxazolyl, ~~3~~, ~~4~~ or 5-isoxazolyl, ~~2~~, ~~4~~ or 5-thiazolyl, ~~3~~, ~~4~~ or 5-isothiazolyl, ~~2~~, ~~3~~ or 4-pyridyl, ~~2~~, ~~4~~, ~~5~~ or 6-pyrimidinyl, furthermore preferably 1,2,3-triazol-1, ~~4~~ or 5-yl, 1,2,4-triazol-1, ~~3~~ or 5-yl, 1- or 5-tetrazolyl, 1,2,3-oxadiazol-4 or 5-yl, 1,2,4-oxadiazol-3 or 5-yl, 1,3,4-thiadiazol-2 or 5-yl, 1,2,4-thiadiazol-3 or 5-yl, 1,2,3-thiadiazol-4 or 5-yl, 3 or 4-pyridazinyl, pyrazinyl, 1, ~~2~~, ~~3~~, ~~4~~, ~~5~~, ~~6~~ or 7-indolyl, ~~4~~ or 5-isindolyl, 1, ~~2~~, ~~4~~ or 5-benzimidazolyl, 1, ~~3~~, ~~4~~, ~~5~~, ~~6~~ or 7-benzopyrazolyl, ~~2~~, ~~4~~, ~~5~~, ~~6~~ or 7-benzoxazolyl, ~~3~~, ~~4~~, ~~5~~, ~~6~~ or 7-benzisoxazolyl, ~~2~~, ~~4~~, ~~5~~, ~~6~~ or 7-benzothiazolyl, ~~2~~, ~~4~~, ~~5~~, ~~6~~ or 7-benzisothiazolyl, ~~4~~, ~~5~~, ~~6~~ or 7-benz-2,1,3-oxadiazolyl, ~~2~~, ~~3~~, ~~4~~, ~~5~~, ~~6~~, ~~7~~ or 8-quinolyl, 1, ~~3~~, ~~4~~, ~~5~~, ~~6~~, ~~7~~ or 8-isoquinolyl, ~~3~~, ~~4~~, ~~5~~, ~~6~~, ~~7~~ or 8-cinnolinyl, ~~2~~, ~~4~~, ~~5~~, ~~6~~, ~~7~~ or 8-quinazolinyl, 5 or 6-quinolinalinyl, ~~2~~, ~~3~~, ~~5~~, ~~6~~, ~~7~~ or 8-2H-benzo[1,4]oxazinyl, 1,3-benzodioxol-5-yl, 1,4-benzodioxan-6-yl, 2,1,3-benzothiadiazol-4 or 5-yl, 2,1,3-benzoxadiazol-5-yl, 2,3-dihydro-2, ~~3~~, ~~4~~ or 5-furyl, 2,5-dihydro-2, ~~3~~, ~~4~~ or 5-furyl, tetrahydro-2 or 3-furyl, 1,3-dioxolan-4-yl, tetrahydro-2 or 3-thienyl, 2,3-dihydro-1, ~~2~~, ~~3~~, ~~4~~ or 5-pyrrolyl, 2,5-dihydro-1, ~~2~~, ~~3~~, ~~4~~ or 5-pyrazolyl, 1, ~~2~~ or 3-pyrrolidinyl, tetrahydro-1, ~~2~~ or 4-imidazolyl, 2,3-dihydro-1, ~~2~~, ~~3~~, ~~4~~ or 5-pyrazolyl, tetrahydro-1, ~~3~~ or 4-pyrazolyl, 1,4-dihydro-1,

~~2, 3 or 4 pyridyl, 1,2,3,4 tetrahydro 1, 2, 3, 4, 5 or 6 pyridyl, 1, 2, 3 or 4 piperidinyl, 2, 3 or 4 morpholinyl, tetrahydro 2, 3 or 4 pyranyl, 1,4 dioxanyl, 1,3 dioxan 2, 4 or 5 yl, hexahydro 1, 3 or 4 pyridazinyl, hexahydro 1, 2, 4 or 5 pyrimidinyl, 1, 2 or 3 piperazinyl, 1,2,3,4 tetrahydro 1, 2, 3, 4, 5, 6, 7 or 8 quinolyl, 1,2,3,4 tetrahydro 1, 2, 3, 4, 5, 6, 7 or 8 isoquinolyl, 2, 3, 5, 6, 7 or 8 3,4 dihydro 2H benzo[1,4]oxazinyl, 2,3 methylenedioxyphenyl, 3,4 methylenedioxyphenyl, 2,3 ethylenedioxyphenyl, 3,4 ethylenedioxyphenyl, 3,4 (difluoromethylenedioxy)phenyl, 2,3 dihydrobenzofuran 5 or 6 yl, 2,3 (2-oxomethylenedioxy)phenyl, 3,4 dihydro 2H 1,5 benzodioxepin 6 or 7 yl, 2,3 dihydrobenzofuranyl or 2,3 dihydro 2-oxofuranyl,~~
each optionally substituted by R³ and/or R⁴.

18. (Canceled)

19. (Previously presented) A compound of claim 1, wherein R³ and R⁴ are both H.